Stifel reiterates Buy on Envista stock, keeps $31 price target
Stifel maintained its Buy rating and $31.00 price target on Envista Holdings Corp. (NYSE:NVST) after the company's 2026 Investor Day, citing upwardly revised financial objectives and market share gains. The stock trades at $23.69, with analysts noting significant upside potential. JPMorgan upgraded its rating to Overweight with a $32.00 target, while BMO and Mizuho reiterated their ratings. Envista also announced leadership changes and a revised compensation package for its CEO.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a new price target suggest a bullish short‑term bias.
Market read
Analyst consensus upgrades could drive NVST higher, influencing the dental equipment niche.
What to watch
Execution risk on margin expansion and competitive pressure in consumables.
Background
Envista recently held its 2026 Investor Day and disclosed leadership changes.
Ticker impact
Stifel reiterates Buy rating with a $31 price target and JPMorgan upgrades Envista, plus a CEO appointment as board chair.
Potential upside of 30% from current levels if target is reached.
Multiple analyst upgrades and a clear price target provide a fresh catalyst, though no material financial data is disclosed.
Market effects
Positive outlook may benefit broader dental equipment sector.
U.S. market sentiment for health‑care equipment could improve.
Limited to U.S. listed dental supplies companies.
Counterpoint
Rating reiterations may already be priced in; upside could be limited.
Key entities
- companyEnvista Holdings Corp.
Dental products manufacturer (NYSE:NVST).
- analystStifel
Maintains Buy rating with $31 target.
- analystJPMorgan
Upgraded to Overweight with $32 target.
